Che luglio 2026 Il voto ha fatto e cosa ha lasciato aperto
Il comitato consultivo sui composti farmaceutici si è riunito a luglio 23 E 24, 2026 prendere in considerazione sette peptidi candidati per l'inclusione nel 503Un elenco sfuso di sostanze farmaceutiche - l'elenco affermativo che consente ai medici e ai farmacisti autorizzati dallo stato di preparare composti utilizzando una sostanza sfusa che non ha una monografia USP applicabile e non è un componente di un prodotto farmaceutico approvato. Sotto 21 CFR 216.23(C), La FDA valuta quattro cose: caratterizzazione fisica e chimica della sostanza, problemi di sicurezza sollevati dal suo utilizzo nei prodotti composti, prova dell’efficacia o della sua assenza, e uso storico nei farmaci composti.
Lo staff professionale della FDA è stato rilasciato documenti informativi a giugno 29, 2026 raccomandando di non aggiungere nessuno dei sette. Su sei la commissione ha votato diversamente.
|
Peptide (Valutate le forme di base libera e di acetato) |
Utilizzo proposto rivisto |
Voto riportato |
Esito del comitato |
|---|---|---|---|
|
BPC-157 |
Colite ulcerosa |
8–6, 1 astensione |
Consigliato per l'inclusione |
|
KPV |
Guarigione delle ferite e condizioni infiammatorie |
8–6, 1 astensione |
Consigliato per l'inclusione |
|
TB-500 |
Guarigione delle ferite |
8–6, 1 astensione |
Consigliato per l'inclusione |
|
c-PAROLE |
Obesità e osteoporosi |
7–5, 2 astensioni |
Consigliato per l'inclusione |
|
Non ascoltare |
Ischemia cerebrale, emicrania, nevralgia del trigemino |
8–5, 1 astensione |
Consigliato per l'inclusione |
|
Epitalon |
Insonnia |
7–4, 1 astensione |
Consigliato per l'inclusione |
|
Emideltide (DSIP) |
Astinenza da oppioidi, insonnia cronica, narcolessia |
6–7, 1 astensione |
Non raccomandato |
Conteggi dei voti come riportato da RAP e altri punti vendita che coprono il mese di luglio 2026 Voto sui peptidi PCAC.
Cosa ha fatto la FDA: convocò il comitato, documenti informativi pubblicati, e ha ricevuto una raccomandazione consultiva su sei sostanze.
Ciò che la FDA non ha fatto: aggiunto qualsiasi peptide all'elenco dei bulk 503A, autorizzato qualsiasi capitalizzazione, o approvato qualsiasi prodotto. L'aggiunta di una sostanza all'elenco richiede una regolamentazione in materia di avvisi e commenti, che non si era concluso. Lo status normativo di tutti e sette i peptidi è rimasto invariato in base alle votazioni.
Due ulteriori fatti impediscono che questa storia sia chiusa. La FDA ha annunciato un ulteriore incontro del comitato consultivo prima della fine di febbraio 2027 per esaminare ulteriori peptidi, secondo quanto riferito, include GHK-Cu, melanotano II, catelicidina (LL-37), diesa acetato, e fattore di crescita meccano pegilato. E a luglio 2026 La FDA ha ritirato la sua 2021 linee guida sui prodotti farmaceutici peptidici sintetici altamente purificati che fanno riferimento a farmaci elencati di origine rDNA, dicendo che non rifletteva più l’attuale pensiero scientifico, pur affermando che intende riemetterlo. Il quadro si sta muovendo, non accontentarsi.
La conseguenza pratica per un'organizzazione di sintesi: il risultato specifico dell’elenco dei peptidi della FDA conta molto meno dello standard probatorio applicato ai dati sulla qualità dei peptidi. Questo standard è ora visibile nei documenti pubblici, ed è lo stesso standard che un programma dovrà affrontare se l’eventuale domanda è una petizione aggravata, un’applicazione sperimentale per un nuovo farmaco, o un audit di qualificazione del fornitore.
Perché il disaccordo riguardava principalmente le pratiche burocratiche
Leggi i materiali informativi della FDA ed emerge uno schema che è facile non notare nella copertura focalizzata sui conteggi dei voti. Le obiezioni dell’agenzia alla caratterizzazione non erano argomentazioni secondo cui i peptidi non potevano essere caratterizzati. Erano risultati che i pacchetti presentati non li caratterizzavano.
IL analisi dei documenti informativi della FDA pubblicati da Bass, Bacca & Sims riassume il risultato principale: Non è possibile sviluppare standard di qualità significativi se l’identità chimica di una sostanza non è ben stabilita. Il personale della FDA ha riferito che la letteratura e le fonti commerciali spesso descrivono sostanze con lo stesso nome comune nonostante le differenze nella sequenza aminoacidica, o senza chiarire se il materiale è una base libera, un sale, o un estere - e notò che diverse forme di sale e di estere della stessa porzione attiva possono comportarsi diversamente in termini fisico-chimici, tossicologico, e termini farmacocinetici.
Il case del BPC-157 ne è l'esempio più nitido. La FDA ha riferito di aver riscontrato più sostanze commercializzate con un unico nome comune contenenti diverse frazioni attive, e ha osservato che il nome comune non segue le convenzioni stabilite della nomenclatura chimica. Potrebbe esserci, secondo il punto di vista dichiarato dell’agenzia, nessuna base affidabile per presumere che un dato nome identifichi sempre la stessa struttura e forma.
Tre ulteriori carenze si sono ripetute nel set:
-
I test sugli attributi critici di qualità erano scarsi. Le candidature e le informazioni pubbliche spesso mancavano di dati sulle impurità peptidiche, aggregati, qualità microbica, and bacterial endotoxins — all relevant for injectable dosage forms.
-
Method detail was insufficient. FDA stated it could not evaluate how identity, purezza, and impurities were measured from the materials provided. A percentage purity figure without a named chromatographic method and the supporting chromatograms is not an assessable claim.
-
Impurity work was not comparative. What FDA wanted was a full impurity profile — identification, quantification, and control across batches and sources — rather than isolated residual values.
Immunogenicity risk threaded through the safety discussion, particularly for injected peptides where impurities and aggregates are not adequately controlled.
None of those four findings requires a novel scientific method. Each of them requires records that a synthesis organization either keeps or does not.
Dominio 1 — Identità: I tuoi dati possono dimostrare quale molecola hai creato??
Identity is the domain FDA treated as foundational in its evaluation of 503A bulks list peptides, and the standard it applied is stricter than most certificates of analysis imply. A single mass confirmation for the intact molecule establishes molecular weight. It does not establish sequence, it does not distinguish an isomer, and it does not tell a reviewer whether the material is a free base or an acetate salt.
No single technique closes that gap. The frameworks converge on requiring orthogonal methods — separate techniques that could each independently fail, and that rest on different physical principles. The EMA synthetic-peptide guideline, ad esempio, expects identity to be supported by at least two orthogonal methods.
|
Record check |
Why it matters if absent |
|---|---|
|
Intact mass by LC-MS or ESI-MS with the instrument, ionization mode and sample preparation stated |
A mass value with no method attached cannot be reproduced or challenged, and reproducibility is what makes a result usable |
|
Sintesi peptidica Sequence-level confirmation — peptide mapping, Frammentazione MS/MS, or N-terminal sequencing plus amino acid analysis |
Molecular weight alone is compatible with sequence variants and positional isomers |
|
Amino acid composition by amino acid analysis, per Capitolo Generale dell'USP <1052> Biotechnology-Derived Articles — Amino Acid Analysis |
Composition and identity are distinct; a composition result also anchors net content |
|
Explicit declaration of the salt or free-base form, with counterion identity |
Different forms of the same moiety differ in physicochemical and pharmacokinetic behaviour |
|
IL capacità di sintesi peptidica personalizzata and synthesis route recorded against the batch |
Route determines the impurity spectrum; without it, a reviewer cannot Peptidi sintetici judge whether the impurity control strategy fits the chemistry |
The last item is where identity documentation and process documentation meet. A sequence made by solid-phase synthesis with a particular coupling strategy has a predictable failure pattern — truncations, eliminazioni, epimerization at specific residues. A record that names the route makes those risks assessable. A record that lists only a final mass does not.
Dominio 2 — Purezza: Il tuo numero è riproducibile da qualcun altro?
A purity percentage is the most quoted and least informative figure on a typical peptide CoA. It answers one question — what fraction of the ultraviolet-absorbing material in the sample corresponds to the main peak — and it is silent on several others that determine whether the number means anything.
Method purity is not the same as peptide content. Acqua, contromisure, solventi residui, and non-UV-absorbing contaminants sit outside what a chromatographic purity figure captures. A sample reported at 98% purity by area can contain meaningfully less peptide by mass once those components are accounted for. Reporting both, and labelling which is which, is the difference between a measurement and a marketing number.
|
Record check |
Why it matters if absent |
|---|---|
|
Chromatographic purity by RP-HPLC with column, gradient, detection wavelength and integration parameters stated |
Method-dependent figures cannot be compared across suppliers or across years |
|
The chromatogram itself, not a summary figure |
A shoulder, a late-eluting cluster or a baseline issue is visible in the trace and invisible in the number |
|
Peptide content on a counterion-free, anhydrous basis |
Without it, the reported purity and the actual deliverable mass do not reconcile |
|
Water content and counterion content, measured |
These are the two largest non-peptide contributors by mass in lyophilized material |
|
Peptide quality control and release documentation structured so each batch result links to the specification in force at release |
Release without a versioned specification makes lot-to-lot comparison meaningless |
Lot-to-lot consistency deserves separate mention because it is the claim most often asserted and least often evidenced in custom peptide synthesis documentation. Consistency is not a property of any single batch. It is a property of a data set — which means the evidence is a trend across lots against fixed criteria, not a certificate for the lot in hand. If a supplier cannot produce that trend, “lot-to-lot consistency” in a specification is a statement of intent rather than a demonstrated control.
Dominio 3 — Metodi analitici: Un revisore potrebbe ricostruire il tuo metodo?
FDA’s stated complaint was not that the analytical results were wrong. It was that the materials did not provide enough method-specific information to judge whether the results were reliable. That distinction matters, because it means the fix is descriptive rather than experimental.
For each method used to support a specification, a reviewer needs enough detail to understand what was measured and to form a view on whether the method can do what it claims. What a method must demonstrate before its numbers are usable is set out in Io Q2(R2) on the validation of analytical procedures, and the chromatographic parameters an implied method must state are defined in USP <621> Chromatography.
|
Record check |
Why it matters if absent |
|---|---|
|
Full method description: column chemistry and dimensions, mobile phase, gradient table, flow rate, column temperature, lunghezza d'onda di rilevamento |
An implied method is not a method; a reviewer cannot assess specificity without it |
|
System suitability results for the run |
System suitability is the evidence that the run was fit for purpose before the sample was injected |
|
Representative chromatograms for reference standard, sample and, ove rilevante, a spiked or stressed sample |
Specificity is demonstrated by what the method resolves, not by assertion |
|
Validation or verification data covering accuracy, precisione, specificità, linearity and range for the intended use |
Unvalidated numbers cannot support a specification, in any regulatory context |
|
Peptide analytical testing services scope stated explicitly, with a clear line between tests performed in-house and tests subcontracted |
Subcontracted testing is normal; undisclosed subcontracted testing is a documentation failure |
|
Reference standard identity, source, and qualification record |
Every quantitative result is traceable to a standard, and an unqualified standard undermines all of them |
A useful test: hand the method section to a competent analyst who has never worked on the molecule and ask them to reproduce the run. If they cannot, the section is not finished. This is a lower bar than validation and it catches the majority of real gaps.
Dominio 4 — Profili di impurità peptidiche: Cosa si aspetta il processo di elenco dei peptidi della FDA
This is where the July 2026 record is most specific and where threshold numeracy matters most.
Synthetic peptides sit in an unusual regulatory position. The EMA synthetic-peptide guideline states that synthetic peptides are fully or partially excluded from the scope of ICH Q3A and Q3B, ICH Q6A and Q6B, and ICH M7, and instead applies peptide-specific impurity thresholds anchored to the European Pharmacopoeia general monograph. FDA’s synthetic peptide guidance has treated ICH Q3A and Q3B as a general framework with peptide-specific modifications. Either way, the small-molecule impurity table does not apply unchanged, and a program should be able to state which framework it is following and why.
|
Struttura |
Report |
Identify |
Qualify or control |
|---|---|---|---|
|
FDA synthetic peptide guidance (2021; withdrawn July 2026, reissue planned) |
— |
Each peptide-related impurity at ≥0.10% of the drug substance |
New specified peptide-related impurity not above 0.5% of the drug substance |
|
FDA revised draft product-specific guidances (July 2026) |
>0.1% |
>0.5% |
Shared impurities at or below the reference-listed-drug level or 1.0%, whichever is higher |
|
Linee guida EMA sullo sviluppo e la produzione di peptidi sintetici |
>0.1% |
>0.5% |
>1.0% |
Reported tier details vary across secondary summaries of the July 2026 drafts, e il 2021 guidance was withdrawn with a reissue pending — so treat any single number here as framework-specific and verify the current document before you rely on it in a submission. The structural point is stable even though the numbers may shift: peptide-related impurities are governed by their own thresholds, and they are low.
What that means for the peptide impurity profile a program should hold:
|
Record check |
Why it matters if absent |
|---|---|
|
Related substances reported by a named method down to the reporting threshold, with each peak above it accounted for |
An unlisted peak is an unidentified impurity, and unidentified impurities cannot be qualified |
|
Structural assignment for each impurity above the identification threshold — sequence, modification site, or both |
Troncamenti, eliminazioni, residui epimerizzati, deamidated and oxidized variants each carry different risk and are not interchangeable Produzione di peptidi |
|
Non-peptide impurities addressed under their own frameworks: solventi residui in ICH Q3C, elemental impurities under ICH Q3D, mutagenic impurities under ICH M7 |
Peptide-related impurities are only one class; a specification that stops there is incomplete |
|
A documented nitrosamine risk assessment covering amines, nitrosating agents and reaction conditions |
This is now an expectation rather than an option, and it applies to reagents as much as to the peptide |
|
Aggregation and higher-molecular-weight species assessed, with the method named |
Aggregates are immunogenicity-relevant and largely invisible to a standard reversed-phase purity method |
|
Batch-to-batch impurity trend data, not a single-lot profile |
Control is demonstrated by stability of the profile over time, which one lot cannot show |
The commercial argument for doing this work before anyone asks is straightforward. Impurity characterization is cheapest at the point when the chemistry is still being adjusted. Once a specification is fixed and a program has committed to a supplier, an unidentified impurity at 0.6% becomes a deviation, a retest, and possibly a reformulation of the control strategy. The peptide impurity profile FDA expects under current guidance is not new in kind; the July 2026 record simply made it unusually visible.
Dominio 5 — Approvvigionamento: Puoi tornare indietro ai suoi aminoacidi?
This is the domain that received the least public attention and carries the most unexamined risk. Compounding-list coverage focused on the peptide. FDA’s characterization questions, and the general expectations for peptide starting materials, reach all the way back to the amino acid derivatives, resine, and solvents that went into the synthesis.
Capitolo Generale dell'USP <1504> addresses quality attributes of starting materials for the chemical synthesis of therapeutic peptides and is intended to be used alongside the peptide drug substance chapter. It names the non-amino-acid-derivative impurity risks these materials carry: residual solvents and reagents left over from their own preparation, elemental impurities, and transmissible spongiform encephalopathy or bovine spongiform encephalopathy risk. ICH Q7 Chapter 7 sets the materials management baseline — each raw material batch recorded with manufacturer name, identità, quantity, supplier, and supplier control number, purchased against agreed specifications, and traceable into the batches where it was used.
|
Record check |
Why it matters if absent |
|---|---|
|
Approved specification and CoA for every critical raw material batch, reviewed against that specification before use |
A CoA filed without review is a document, non un controllo |
|
Supplier qualification records including audit or assessment status and a change-notification commitment |
Undisclosed supplier process or site changes are the most common route to an unexplained batch shift |
|
Manufacturer name and supplier control number for each raw material lot, with linkage to the peptide batches in which it was used |
Without forward and backward traceability, a raw material problem cannot be bounded to affected batches |
|
Residual solvent declarations or test results aligned to ICH Q3C |
Solvent carryover from a derivative becomes a peptide impurity |
|
Elemental impurity risk assessment aligned to ICH Q3D, covering contributions from materials, catalysts and equipment |
Metal content in a peptide is usually inherited, not introduced |
|
TSE/BSE statements for any animal-derived or potentially animal-derived material, with species and origin |
Origin questions surface late and are expensive to answer retrospectively |
Two practical points. Primo, the manufacturer of a critical material should always be known and documented — not just the distributor. Identity of the actual producer is what makes a supply risk assessable. Secondo, change control is the part of supplier qualification most often left verbal. A written commitment to notify before a process or site change is what converts a supplier relationship into a managed one. Programs that outsource synthesis support with a peptide CRO services partner inherit that partner’s supply chain, so the same traceability questions apply one layer further up.
Dominio 6 — Uso previsto: Le tue specifiche corrispondono al percorso e alla dose?
Here the July 2026 record offers the clearest lesson about specifications generally. Every one of the seven peptides was evaluated for a specific proposed use. The committee that reviewed BPC-157 considered ulcerative colitis. Semax was reviewed for cerebral ischemia, emicrania, and trigeminal neuralgia. Emideltide was assessed for opioid withdrawal, insonnia cronica, and narcolepsy, and FDA’s stated concern included the absence of safety data for the subcutaneous route in particular.
That is not a detail of the compounding framework. It is the general principle: the specification follows the intended use, the route, and the dose — not the molecule name in isolation.
The EMA synthetic-peptide guideline makes the same point structurally. It applies to synthetic peptides used in a medicinal product, distinguishes research-use-only material from pharmaceutical material, expects the counterion to be identified with its stoichiometry, and expresses peptide content on a counterion-free, anhydrous basis within a mass-balance approach to content and purity. A material that is entirely adequate for in vitro screening can be inadequate for an injectable formulation, and the specification is where that difference lives.
|
Record check |
Why it matters if absent |
|---|---|
|
Intended use stated explicitly on the specification: research use, further manufacturing, or a defined clinical route |
Specification content cannot be justified without the use it is written for |
|
Route of administration, dose level, and dosing duration recorded where a clinical use is contemplated |
Qualification thresholds and endotoxin limits depend on these inputs |
|
Purezza, contenuto, controione, acqua, and residual solvent criteria set to that use rather than to a house default |
A default specification is a specification nobody has justified |
|
Microbiological and endotoxin criteria appropriate to the route, with the test method named |
The endotoxin method and limit differ materially between a non-sterile research reagent and an injectable |
|
A stated position on whether the material supports that use, and what would be required to support a different one |
Programs that never state the boundary tend to cross it by accident |
The last row is deliberately uncomfortable. Being able to say “this material is qualified for X and would need Y before it could support Z” is more useful to a reviewer and a partner than a specification broad enough to permit everything and specific enough to prove nothing. It is also the record most often missing, because it requires a decision rather than a measurement. For teams designing peptide variants toward a target profile, the same logic applies one step earlier — read across the protein engineering lessons for peptide optimization to see how design intent constrains the quality attributes worth tracking from the first batch.
Punteggio del pacchetto prima che lo faccia qualcun altro
FDA’s four criteria give a program something better than a checklist: they imply a scoring rule that predicts which parts of a documentation package will be challenged. The criterion that receives the most attention publicly is characterization, but the one that sinks petitions is usually the weakest link rather than the average.
|
Dominio |
Evidence a reviewer can act on |
Typical weak point |
|---|---|---|
|
Identità |
Two orthogonal methods, salt form declared, route recorded |
Single intact mass standing in for sequence confirmation |
|
Purezza |
Method-qualified figure plus counterion-free content, water and counterion measured |
A percentage with no method and no content basis |
|
Metodi analitici |
Full method description, system suitability, validation data, representative traces |
Implied methods and summary chromatograms |
|
Impurity profiles |
Every peak above the threshold assigned; non-peptide classes covered; trend data |
Isolated residual values presented as a profile |
|
Approvvigionamento |
Manufacturer named, lot traceability into batches, change-control commitment |
Distributor name only, verbal change control |
|
Intended use |
Use and route stated, criteria justified, boundary stated |
House-default specification |
The scoring discipline that matters is not adding up the good rows. It is identifying the one domain where the program would have nothing to say if asked, and closing that gap first. Work on the strong domains is comfortable and mostly adds documentation weight; work on the weak domain is what changes the outcome.
A second practical step is to convert these tables into a vendor questionnaire and answer it as though it were being asked by someone else. Most programs find that the material they can produce readily — chromatograms, spettri di massa, CoAs — maps onto the domains they are already strong in, while the domains that depend on deliberate record-keeping, sourcing traceability and intended-use justification, require decisions they have not yet made. That asymmetry is predictable, and it is better found internally than during a review.
None of this depends on how the rulemaking concludes or what the February 2027 committee does with a further set of peptides. The record set described in this peptide documentation checklist is what any peptide program should be able to produce to describe its own material honestly — to a regulator, to a partner conducting due diligence, or to its own quality function during an investigation to which external review is a detail rather than the trigger.
Prossimi passi
If any of the six domains above came back thin, the useful next move is a technical review of the specific gaps rather than a general quality claim. MOL Changes works with development teams on exactly that: walking through an existing documentation package against identity, purezza, methodological, impurity, sourcing, and intended-use expectations, and identifying what a lot-specific data package would need to include to close the gap. If that would help your program, ask for a technical feasibility assessment and we will tell you plainly what your current records support, what they do not, and what it would take to get there.
